(2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth. In 2022, THTX's revenue was 80. 1-514-336-7800. MONTREAL, Feb. W. MONTREAL, March 07, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. $30. TH | September 5, 2023. 2022 Revenue Guidance Theratechnologies anticipates fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the. com. com uses cookies on this site. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers Stockhouse. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650For the three- and six-month periods ended May 31, 2023, consolidated revenue was $17,549,000 and $37,457,000, compared to $19,268,000 and $37,825,000 for the same periods ended May 31, 2022. Phone Number (514) 336-7800. By continuing to use our service, you agree to our use of cookies. The website address for Stockhouse has changed We changed the address of the Stockhouse website from to stockhouse. Stockhouse. com uses cookies on this site. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. -based clinical sites participating in the conduct of the Phase. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. communications@theratech. com uses cookies on this site. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound. Theratechnologies reduces R&D head count to compensate for sales setback. com. Stockhouse. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. FDA for its IV push form of administration of Trogarzo. MONTREAL, Oct. MONTREAL, Sept. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. TH | September 26, 2023. : 001-35203 Mr. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies Inc. Shares of Theratechnologies are up 4. Theratechnologies had a negative net margin of 36. Theratechnologies was founded in 1993 and currently employs more than 150 people in Canada, the United States and Europe. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors Stockhouse. 4%. Gary Littlejohn. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. Theratechnologies inc. : Renegotiated Lease to Generate Substantial Annual Savings Stockhouse. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April 12. (2022-02-10 | TSX:TH) Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. We also use them to share usage information with our partners. Non-Profit & Charitable Organizations · United States · <25 Employees. GUD | Complete Knight Therapeutics Inc. - October 10, 2023) - KO Gold Inc. TH | February 28, 2023. 38. TH 48% v4,15M c1. Theratechnologies' (TH) Senior Vice President and Chief Medical Officer Dr. Type: Company - Public (TH) Revenue: $5 to $25 million (USD) Biotech & Pharmaceuticals. Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including. RESSOURCES. com. A high-level overview of Theratechnologies Inc. Theratechnologies (TSX: TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 40 f102M H1. Company Participants. Rosenberg, Reference is made to your letter dated August 16, 2012 regarding the Form 40-F for fiscal year-end November 30, 2011 filed by Theratechnologies Inc. Approximately US$2,000,000, or CA$2,600,000, was paid in cash at closing. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650WELCOME TO SEDAR+ File, disclose and search for issuer information in Canada’s capital markets Search SEDAR+ All public disclosure documents Reporting Issuers List Filing organizations from all jurisdictions Disciplined List People and companies under disciplinary action Cease Trade Orders People and companies restricted from trading securities Sign. (NASDAQ:NASDAQ:THTX) Q1 2022 Earnings Conference Call April 13, 2022 8:30 AM ETCompany ParticipantsPaul Levesque - President & CEOPhilippe Dubuc - SVP &. Herein, we report. Stockhouse. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 's motion for leave to commence. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. 5%. MONTREAL, Dec. R. MONTREAL, Oct. (2020-10-22 | TSX:TH) Theratechnologies to Present at Upcoming Investor Conferences on October 29 and November 10, 2020. 31K. Theratechnologies is pepped up on peptides. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. $44. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) ), a biopharmaceutical company focused on the development. 06 million, an increase of 14. 250 Howe Street, Suite 1400 Vancouver, British Columbia, V6C 3S7 Click to expand. . By continuing to use our service, you agree to our use of cookies. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. ET. Theratechnologies, Inc. 08). (TSX: EXRO) (OTCQB: EXROF) (the "Company" or "Exro" ), a leading clean technology company which has developed a new class of power electronics for electric motors and powertrains, announced today its financial results for the three months ended March 31, 2022. Find the latest Theratechnologies Inc. Theratechnologies, Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. Find the latest Theratechnologies Inc. MONTREAL, Sept. By exploiting the SORT1 function in ligand internalization, a new anticancer treatment strategy was designed to target SORT1‐positive TNBC‐derived cells both in vitro and in two in vivo tumor xenografts. Theratechnologies inc. MONTREAL, Jan. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced public offering (the “Public. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced an update on the plan to amend and optimize the protocol of its Phase 1 oncology. By continuing to use our service, you agree to our use of cookies. 51 to 200 Employees. (2020-03-31 | tsx:th) theratechnologies provides business update related to current covid-19 situation Stockhouse. " The 12-month stock price forecast is $18. By continuing to use our service, you agree to our use of cookies. MONTREAL, July 07, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. . Investor inquiries: Elif McDonald. Theratechnologies Inc. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the. . (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business. We also use them to share usage information with our partners. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1. 89 $2. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing. com uses cookies on this site. , a biopharmaceutical company, engages in the discovery of therapeutic products for commercialization. For investor inquiries: Leah Gibson. By continuing to use our service, you agree to our use of cookies. We currently market prescription products for people with HIV in the United States. We also use them to share usage. We also use them to share usage information with our partners. (CSE: KOG) (" KO Gold " or the " Company ") is pleased to announce that the common shares of the Company will commence trading on the Canadian Securities Exchange (CSE) effective at the open of business on Wednesday, October 11, 2023, under the symbol " KOG ". [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. According to 3 analysts, the average rating for THTX stock is "Buy. , a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced further changes to its operations that will see a tapering. By continuing to use our service, you agree to our use of cookies. THTX | Complete Theratechnologies Inc. Theratechnologies was founded in 1993 and is headquartered in Montreal, Canada. MONTREAL, Oct. Theratechnologies Inc. Canada’s largest financial portal for Canadian small-cap investors is right here at Stockhouse where our Bullboards are a leading forum. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. Theratechnologies layoffs. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second quarter. Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. 2% for this period. MONTREAL, Sept. . This module allows you to check different measures of market premium (i. 75%. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City Stockhouse. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH) in. 05M. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. , Senior Vice President and Chief Medical Officer, Theratechnologies commented, “The exciting new data in triple negative breast and ovarian cancer demonstrate. . Learn why it. By continuing to use our service, you agree to our use of cookies. 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theratechnologies Inc. Further. Theratechnologies will acquire all outstanding shares of Katana for US$5,300,000 or CA$6,900,000. Cookies are used to offer you a better browsing experience and to analyze our traffic. com uses cookies on this site. Currency in USD Follow 2W 10W 9M 1. However, it did not meet the equivalence limits of 0. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as compared to the 2021 fiscal year. Theratechnologies Inc (Theratechnologies) is a biopharmaceutical company that focuses on the discovery and development of drugs for people with orphan medical conditions. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. By continuing to use our service, you agree to our use of cookies. BioSyent then managesthese products through the regulatory process and product registration (approval); and once approved, BioSyent markets these products throughout Canada. Company Type For Profit. com uses cookies on this site. Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022. Theratechnologies Announces Operational Update - read this article along with other careers information, tips and advice on BioSpace Theratechnologies Inc. 00. (2015-07-23 | TSX:TH) Theratechnologies Announces $9,600,000 Firm Offering of Units and Filing of Preliminary Short Form Prospectus. This news release constitutes a "designated news release" for the purposes of. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. Trogarzo is a CD4-directed post-attachment HIV-1 inhibitor. com uses cookies on this site. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. During the last trading day the stock fluctuated 12. com uses cookies on this site. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. (882) posted 3 minutes ago. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter of fiscal 2022 ended May 31 on Thursday, July 14, 2022. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. - Cash, bonds and money market funds of US$22. Track Theratechnologies Inc. FAQ – Utilisateurs de TMX Argent NOUVEAU. P. By continuing to use our service, you agree to our use of cookies. T. T. Theratechnologies Inc. (2019-08-12 | TSX:TH) Theratechnologies Files Application to List on NASDAQ. Top 173 largest Canadian Companies in the Drug Manufacturers—Specialty & Generic industry by Market Cap. TORONTO, May 19, 2023 /CNW/ - This press release is being disseminated as required by. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced preliminary efficacy data from a Phase 1 study of its lead investigational peptide-drug. 20% from a day low at $1. Stockhouse. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. MONTREAL, Dec. MONTREAL, Aug. Small cap stock market news and analysis, portfolio tracking, investor message boards and forums (bullboards), newsletter aggregation and detailed snapshots of stock quotes for. We also use them to share. (2021-01-19 | TSX:TH) Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. m. TO) on CEO. com uses cookies on this site. Cookies are used to offer you a better browsing experience and to analyze our traffic. 11/05/2020 4:15:02 PM. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a commercial-stage biopharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical. 3089 Background: SORT1 is expressed in a variety of tumors when compared to most healthy tissue. Investor Relations. com uses cookies on this site. GUD | Complete Knight Therapeutics Inc. This news release constitutes a “designated news release” for the purposes. 82 million. Theratechnologies Inc. Background: Breast and ovarian cancer stem cells (CSC) can contribute to the invasive and chemoresistance phenotype of tumors. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced the publication of a preclinical study demonstrating the in vitro and in vivo efficacy of TH1902, an investigational sortilin (SORT1)-targeted peptide-drug conjugate, in inhibiting ovarian cancer and triple-negative breast cancer (TNBC. View real-time stock prices and stock quotes for a full financial overview. stock news by MarketWatch. This suggests a possible upside of 2,471. These companies provide a lot of detail to the OTC Markets Group including audited financials. ASP | Complete Acerus Pharmaceuticals Corp. com. Stockhouse. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. : Renegotiated Lease to Generate Substantial Annual Savings. “This is yet another major achievement for our oncology program. We also use them to share usage. Shares of Theratechnologies are up 4. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). In the United States, Trogarzo ® (ibalizumab. 06 million, an increase of. This peptide-drug conjugate (PDC) is the lead candidate stemming from Theratechnologies’ SORT1+ Technology™ in oncology. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. B2Gold Declares Fourth Quarter 2023 Dividend. Investor Relations. MONTREAL, Jan. TH | March 7, 2023. By continuing to use our service, you agree to our use of cookies. Montréal, Québec, Canada . - 2023 Q3 positive adjusted EBITDA to be achieved. . Register for your free account today at data. 28 $1. Data presented at AMCP Nexus 2023. FY2023 revenue guidance range set between $90 million and $95 million. 22M. Q4 2022 consolidated revenue growth of 14. The company’s marketed products include Egrifta SV is indicated to reduce excess abdominal fat in human immunodeficiency virus (HIV. - Q3 2022 North American Revenue Growth of 19%. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement. was a. About Theratechnologies. Wainwright NASH Investor Conference. (NASDAQ:NASDAQ:THTX) Q1 2021 Earnings Conference Call April 14, 2021 8:30 AM ETCompany ParticipantsDenis Boucher - Vice President,. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. European Headquarters. Stockhouse. By continuing to use our service, you agree to our use of cookies. When this page refreshes you will be logged in with the new address. Stockhouse. (NASDAQ:THTX) Q3 2021 Earnings Call October 13, 2021 8:30 A. com uses cookies on this site. Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TH) provided business highlights and financial results for the second quarter and first half of fiscal year 2022; For the three- and six-month periods ending May 31, 2022, consolidated revenue was US$19,268,000 and US$37,825,000, compared to US$17,787,000 and US$33,217,000 for the same periods last year,. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. 57%) Q1 2020 Earnings Call. View real-time stock prices and stock quotes for a full financial overview. THERATECHNOLOGIES INC. Theratechnologies Appoints New Board Member. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. TH1902 combines Theratechnologies’ proprietary peptide to docetaxel. 2% per year. Stockhouse. . T. Second quarter 2022 earnings: Revenues miss analyst expectations Jul 15. CA, an investment chat community for Canada's small cap marketsTheratechnologies is currently analyzing data and preparing responses to questions received from the FDA. The webinar will also address system-level barriers and present real-world. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies inc. . (2021-03-20 | TSX:TH) Theratechnologies Announces New Data Demonstrating Tesamorelin's Positive Effect on Immune Response Linked to Liver Inflammation. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. View real-time stock prices and stock quotes for a full financial overview. [email protected] Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update T. Follow. T. Senior Director, Investor Relations. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. C. Selected news for Normal, Illinois and Cancer Therapy, which are filed under Locations / US Cities and Healthcare Topics, respectively. (Theratechnologies, or the Company (on a consolidated basis)) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. TH1902 is currently Theratechnologies’ lead investigational peptide drug conjugate candidate for the treatment of cancer derived from its SORT1+ Technology™. (2022-10-03 | TSX:TH) Theratechnologies' Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population. TH | May 19, 2023. Cookies are used to offer you a better browsing experience and to analyze our traffic. a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket portion of the first-in-human study of TH1902, Theratechnologies’ investigational lead peptide drug conjugate (PDC) for the treatment of sortilin-expressing. 7 ( 1D) About THTX In 2022, THTX's revenue was 80. If you have JavaScript enabled then this page should refresh automatically, if it does not then please tap the button below. TH | Complete Theratechnologies Inc. Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the. Trogarzo ® is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor. com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. Lead drug EGRIFTA (tesamorelin for injection) is being marketed for the reduction of excess abdominal fat in HIV-infected patients with. We also use them to share usage. com uses cookies on this site. Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon;. 65 per cent to C$1. 86%. Losses were -47. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. By continuing to use our service, you agree to our use of cookies. M. Stockhouse. This enduring webinar with Drs Arsalan Shah, Sarah Rowan, Stacey Trooskin, and Juliana Wallace will provide critical updates on specific strategies to improve testing and linkage to care, retention in care, and an overview of guidelines for treatment of HIV and HCV. It is the Company’s proprietary. Theratechnologies develops and commercializes innovative therapies. com uses cookies on this site. Q3 2023 consolidated revenue of $20. Read More. (TSX:TH) announced new data from a tissue microarrays study which demonstrated high expression of sortilin 1 in solid tumors. Once expert advice is considered, the Company. 2. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. By continuing to use our service, you agree to our use of cookies. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound (PDC),. TH | October 13, 2022. MONTREAL, Feb. Cookies are used to offer you a better browsing experience and to analyze our traffic. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Theratechnologies has established its SORT1+ Technology™ platform as an engine for the development of proprietary peptide-drug conjugates (PDCs) that target the sortilin (SORT1) receptor, which is expressed in multiple tumor types. TH | July 20, 2023. 3 brokerages have issued 1-year price objectives for Theratechnologies' shares. By continuing to use our service, you agree to our use of cookies. L. H. Cookies are used to offer you a better browsing experience and to analyze our traffic. S. has received a $100 million binding commitment with respect to a non-dilutive term loan with an affiliate of Marathon Asset Management. com uses cookies on this site. com. We also use them to share usage. Proceeds to Be Used to Redeem All of the Outstanding 5. THERATECHNOLOGIES INC. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. TO) Stock Price, News, Quote & History - Yahoo Finance Canada Markets close in 43 mins S&P/TSX 20,125. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Jours fériés des marchés. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. Headquartered in Montreal, Theratechnologies is a biotech company that develops innovative therapies for unmet medical needs in HIV, oncology, and NASH, a type of liver disease. La Bourse de Toronto a perdu. T. MONTREAL, Oct. . 16, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. - 2023 Q3 positive adjusted EBITDA to be. Stockhouse. com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Theratechnologies Inc. UN) today announces steps to strengthen its financial position, including financing and disposition initiatives, and a reduction to its monthly distribution. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its third. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. 66% compared to the previous year's 69. (2015-05-15 | TSX:TH) Authorization to Discontinue Class Action Proceedings Against Theratechnologies Granted.